Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

0:00
2:53
Rewind 15 seconds
Fast Forward 15 seconds
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

More episodes from "Pharmaceutical Executive"